These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 10321509)

  • 1. Phase I study of AG 331, a novel thymidylate synthase inhibitor, in patients with refractory solid tumors.
    Koda RT; Garcia AA; Chatterjee DJ; Li WY; Parimoo D; Jeffers S; Rogers M; Leichman CG; Leichman L; Wu EY; Shetty BV; Webber S; Clendinnin N; Muggia FM
    Cancer Chemother Pharmacol; 1999; 43(6):489-96. PubMed ID: 10321509
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I trial of the thymidylate synthase inhibitor AG331 as a 5-day continuous infusion.
    O'Dwyer PJ; Laub PB; DeMaria D; Qian M; Reilly D; Giantonio B; Johnston AL; Wu EY; Bauman L; Clendeninn NJ; Gallo JM
    Clin Cancer Res; 1996 Oct; 2(10):1685-92. PubMed ID: 9816117
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase I and pharmacokinetic study of 1843U89, a noncompetitive inhibitor of thymidylate synthase, in patients with advanced solid malignancies.
    Schwartz G; Johnson TR; Goetz A; Burris H; Smetzer L; Lampkin T; Sailstad J; Hohneker JA; Von Hoff DD; Rowinsky EK
    Clin Cancer Res; 2001 Jul; 7(7):1901-11. PubMed ID: 11448903
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I trial of ZD1694, a new folate-based thymidylate synthase inhibitor, in patients with solid tumors.
    Clarke SJ; Hanwell J; de Boer M; Planting A; Verweij J; Walker M; Smith R; Jackman AL; Hughes LR; Harrap KR; Kennealey GT; Judson IR
    J Clin Oncol; 1996 May; 14(5):1495-503. PubMed ID: 8622063
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I and pharmacology study of intoplicine (RP 60475; NSC 645008), novel topoisomerase I and II inhibitor, in cancer patients.
    Abigerges D; Armand JP; Chabot GG; Bruno R; Bissery MC; Bayssas M; Klink-Alakl M; Clavel M; Catimel G
    Anticancer Drugs; 1996 Feb; 7(2):166-74. PubMed ID: 8740721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Phase I study of raltitrexed, an antifolate thymidylate synthase inhibitor, in adult patients with advanced solid tumors.
    Grem JL; Sorensen JM; Cullen E; Takimoto CH; Steinberg SM; Chen AP; Hamilton JM; Arbuck SG; McAtee N; Lawrence D; Goldspiel B; Johnston PG; Allegra CJ
    Clin Cancer Res; 1999 Sep; 5(9):2381-91. PubMed ID: 10499608
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Initial phase I evaluation of the novel thymidylate synthase inhibitor, LY231514, using the modified continual reassessment method for dose escalation.
    Rinaldi DA; Burris HA; Dorr FA; Woodworth JR; Kuhn JG; Eckardt JR; Rodriguez G; Corso SW; Fields SM; Langley C
    J Clin Oncol; 1995 Nov; 13(11):2842-50. PubMed ID: 7595747
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Phase I study of raltitrexed (ZD-1694)].
    Horikoshi N; Aiba K; Fukuoka M; Akazawa S; Sakata Y; Furuse K; Kanamaru R; Kudoh S; Konishi T; Kurihara M; Niitani H; Furue H; Tsukagoshi S; Taguchi T; Yoshida S; Ota K; Kotake T; Wakui A
    Gan To Kagaku Ryoho; 1998 Nov; 25(13):2075-84. PubMed ID: 9838910
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical and phase I clinical studies with the nonclassical antifolate thymidylate synthase inhibitor nolatrexed dihydrochloride given by prolonged administration in patients with solid tumors.
    Rafi I; Boddy AV; Calvete JA; Taylor GA; Newell DR; Bailey NP; Lind MJ; Green M; Hines J; Johnstone A; Clendeninn N; Calvert AH
    J Clin Oncol; 1998 Mar; 16(3):1131-41. PubMed ID: 9508200
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors: correlations with clinical characteristics and safety.
    Guo F; Letrent SP; Munster PN; Britten CD; Gelmon K; Tolcher AW; Sharma A
    Cancer Chemother Pharmacol; 2008 Jun; 62(1):97-109. PubMed ID: 17805538
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I and pharmacokinetic study of the nonpolyglutamatable thymidylate synthase inhibitor ZD9331 plus docetaxel in patients with advanced solid malignancies.
    Schwartz GH; Jones CB; Garrison M; Patnaik A; Takimoto C; McCreery H; Skinner M; Tolcher AW; Rowinsky EK
    Invest New Drugs; 2004 Nov; 22(4):437-48. PubMed ID: 15292714
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase I study of the safety and pharmacokinetics of edotecarin (J-107088), a novel topoisomerase I inhibitor, in patients with advanced solid tumors.
    Hurwitz HI; Cohen RB; McGovren JP; Hirawat S; Petros WP; Natsumeda Y; Yoshinari T
    Cancer Chemother Pharmacol; 2007 Jan; 59(1):139-47. PubMed ID: 16819636
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolism, excretion and pharmacokinetics of a single dose of [14C]-raltitrexed in cancer patients.
    Beale P; Judson I; Hanwell J; Berry C; Aherne W; Hickish T; Martin P; Walker M
    Cancer Chemother Pharmacol; 1998; 42(1):71-6. PubMed ID: 9619761
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I and pharmacokinetic study of edotecarin, a novel topoisomerase I inhibitor, administered once every 3 weeks in patients with solid tumors.
    Yamada Y; Tamura T; Yamamoto N; Shimoyama T; Ueda Y; Murakami H; Kusaba H; Kamiya Y; Saka H; Tanigawara Y; McGovren JP; Natsumeda Y
    Cancer Chemother Pharmacol; 2006 Aug; 58(2):173-82. PubMed ID: 16308697
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I study of OSI-7904L, a novel liposomal thymidylate synthase inhibitor in patients with refractory solid tumors.
    Beutel G; Glen H; Schöffski P; Chick J; Gill S; Cassidy J; Twelves C
    Clin Cancer Res; 2005 Aug; 11(15):5487-95. PubMed ID: 16061865
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of impaired renal function on the pharmacokinetics and toxicity of i.v. ZD9331, a novel non-polyglutamated thymidylate synthase inhibitor, in adult patients with solid tumors.
    de Jonge MJ; Glimelius B; Verweij J; Van Groeningen C; Bonneterre J; de Vries EG; Culine S; Young J; Smith R; Droz J
    Anticancer Drugs; 2002 Jul; 13(6):645-53. PubMed ID: 12172511
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical pharmacokinetic and pharmacodynamic studies with the nonclassical antifolate thymidylate synthase inhibitor 3, 4-dihydro-2-amino-6-methyl-4-oxo-5-(4-pyridylthio)-quinazolone dihydrochloride (AG337) given by 24-hour continuous intravenous infusion.
    Rafi I; Taylor GA; Calvete JA; Boddy AV; Balmanno K; Bailey N; Lind M; Calvert AH; Webber S; Jackson RC
    Clin Cancer Res; 1995 Nov; 1(11):1275-84. PubMed ID: 9815922
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I and pharmacologic study of oral ZD9331, a novel nonpolyglutamated thymidylate synthase inhibitor, in adult patients with solid tumors.
    de Jonge MJ; Punt CJ; Sparreboom A; Planting AS; Peters ME; van De Schraaf J; Jackman A; Smith R; de Mulder PH; Verweij J
    J Clin Oncol; 2002 Apr; 20(7):1923-31. PubMed ID: 11919253
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I evaluation of the quinazoline antifolate thymidylate synthase inhibitor, N10-propargyl-5,8-dideazafolic acid, CB3717.
    Calvert AH; Alison DL; Harland SJ; Robinson BA; Jackman AL; Jones TR; Newell DR; Siddik ZH; Wiltshaw E; McElwain TJ
    J Clin Oncol; 1986 Aug; 4(8):1245-52. PubMed ID: 3734849
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I clinical and pharmacologic study of eniluracil plus fluorouracil in patients with advanced cancer.
    Schilsky RL; Hohneker J; Ratain MJ; Janisch L; Smetzer L; Lucas VS; Khor SP; Diasio R; Von Hoff DD; Burris HA
    J Clin Oncol; 1998 Apr; 16(4):1450-7. PubMed ID: 9552051
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.